Susquehanna International Group
CYTK icon

Susquehanna International Group’s Cytokinetics CYTK Stock Holding History

Susquehanna International Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$65.6M Sell
994,800
-433,300
-30% -$27.5M 0.01% 1087
2025
Q4 		$90.7M Buy
1,428,100
+236,800
+20% +$14.7M 0.01% 946
2025
Q3 		$65.5M Buy
1,191,300
+893,200
+300% +$36.8M 0.01% 1161
2025
Q2 		$9.85M Buy
298,100
+48,000
+19% +$1.67M ﹤0.01% 2852
2025
Q1 		$10.1M Sell
250,100
-86,800
-26% -$3.99M ﹤0.01% 2529
2024
Q4 		$15.8M Sell
336,900
-10,200
-3% -$530K ﹤0.01% 2091
2024
Q3 		$18.3M Buy
347,100
+11,800
+4% +$658K ﹤0.01% 1914
2024
Q2 		$18.2M Sell
335,300
-281,600
-46% -$17M ﹤0.01% 1828
2024
Q1 		$43.3M Sell
616,900
-1,991,200
-76% -$154M 0.01% 1132
2023
Q4 		$218M Buy
2,608,100
+2,450,200
+1,552% +$88.7M 0.04% 359
2023
Q3 		$4.65M Buy
157,900
+124,400
+371% +$4.14M ﹤0.01% 3663
2023
Q2 		$1.09M Sell
33,500
-30,900
-48% -$1.14M ﹤0.01% 6472
2023
Q1 		$2.27M Sell
64,400
-39,300
-38% -$1.6M ﹤0.01% 4871
2022
Q4 		$4.75M Sell
103,700
-25,000
-19% -$1.08M ﹤0.01% 3317
2022
Q3 		$6.24M Buy
128,700
+20,000
+18% +$963K ﹤0.01% 2828
2022
Q2 		$4.27M Buy
108,700
+14,200
+15% +$572K ﹤0.01% 3439
2022
Q1 		$3.48M Buy
94,500
+17,800
+23% +$632K ﹤0.01% 4334
2021
Q4 		$3.5M Buy
76,700
+22,100
+40% +$853K ﹤0.01% 4377
2021
Q3 		$1.95M Sell
54,600
-50,900
-48% -$1.5M ﹤0.01% 5887
2021
Q2 		$2.09M Buy
105,500
+55,600
+111% +$1.31M ﹤0.01% 5819
2021
Q1 		$1.16M Sell
49,900
-79,600
-61% -$1.7M ﹤0.01% 7327
2020
Q4 		$2.69M Sell
129,500
-94,200
-42% -$1.72M ﹤0.01% 4501
2020
Q3 		$4.84M Buy
223,700
+165,000
+281% +$3.86M ﹤0.01% 3099
2020
Q2 		$1.38M Sell
58,700
-9,600
-14% -$180K ﹤0.01% 5195
2020
Q1 		$805K Sell
68,300
-13,100
-16% -$167K ﹤0.01% 5878
2019
Q4 		$864K Buy
81,400
+40,500
+99% +$416K ﹤0.01% 5814
2019
Q3 		$465K Sell
40,900
-9,200
-18% -$115K ﹤0.01% 7456
2019
Q2 		$564K Buy
50,100
+11,600
+30% +$112K ﹤0.01% 7038
2019
Q1 		$311K Buy
38,500
+7,800
+25% +$57.3K ﹤0.01% 7140
2018
Q4 		$194K Sell
30,700
-22,800
-43% -$167K ﹤0.01% 7778
2018
Q3 		$527K Buy
53,500
+23,200
+77% +$186K ﹤0.01% 6418
2018
Q2 		$251K Sell
30,300
-52,000
-63% -$433K ﹤0.01% 8179
2018
Q1 		$593K Buy
82,300
+9,400
+13% +$80.6K ﹤0.01% 6279
2017
Q4 		$594K Sell
72,900
-5,000
-6% -$56.8K ﹤0.01% 6309
2017
Q3 		$1.13M Buy
77,900
+6,700
+9% +$91.5K ﹤0.01% 5060
2017
Q2 		$862K Buy
71,200
+6,000
+9% +$83.4K ﹤0.01% 5573
2017
Q1 		$838K Buy
+65,200
New +$762K ﹤0.01% 5503
2016
Q4 		– Sell
-50,900
Closed -$467K – 9635
2016
Q3 		$467K Sell
50,900
-12,700
-20% -$133K ﹤0.01% 6176
2016
Q2 		$604K Sell
63,600
-84,500
-57% -$693K ﹤0.01% 5809
2016
Q1 		$1.04M Buy
148,100
+15,300
+12% +$112K ﹤0.01% 5004
2015
Q4 		$1.39M Buy
132,800
+62,200
+88% +$610K ﹤0.01% 4747
2015
Q3 		$472K Buy
70,600
+12,500
+22% +$85.3K ﹤0.01% 7236
2015
Q2 		$390K Buy
58,100
+19,000
+49% +$125K ﹤0.01% 8068
2015
Q1 		$265K Sell
39,100
-2,300
-6% -$17.2K ﹤0.01% 8201
2014
Q4 		$332K Sell
41,400
-10,500
-20% -$45.1K ﹤0.01% 7958
2014
Q3 		$183K Sell
51,900
-86,900
-63% -$365K ﹤0.01% 8756
2014
Q2 		$663K Sell
138,800
-94,500
-41% -$577K ﹤0.01% 6915
2014
Q1 		$2.22M Buy
233,300
+201,200
+627% +$1.82M ﹤0.01% 4166
2013
Q4 		$209K Sell
32,100
-18,400
-36% -$121K ﹤0.01% 8185
2013
Q3 		$383K Buy
+50,500
New +$542K ﹤0.01% 6837

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna International Group's CYTK Position: Q1 2026 in Review

Susquehanna International Group increased its Cytokinetics (CYTK) stake by 19% in Q1 2026, buying an estimated $9.24M and bringing the position to 898,951 shares worth $59.2M. The position accounts for 0.01% of the portfolio, ranked #1161.

Susquehanna International Group first reported a position in CYTK in Q3 2013 and has held it in 42 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Susquehanna International Group held 898,951 shares of Cytokinetics worth $59.2M as of Q1 2026.
  • Susquehanna International Group bought 145,334 Cytokinetics shares in Q1 2026, an estimated $9.24M.
  • Cytokinetics made up 0.01% of Susquehanna International Group's portfolio in Q1 2026, its #1161 holding.
  • Susquehanna International Group first reported a position in Cytokinetics in Q3 2013 and has held it in 42 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.